VISION Trial Videos

Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris

Details
In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...

The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on the implementation of PSMA theranostics and treating patients with lutetium in clinical practices. Drs Morgans and Sartor talk through the logistics of this integration, patient selection, and treatment choice for prolonging survival and improving quality of life. Dr. Sartor also highlights potential novel expanded indications that we may see i...

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on implementation strategies for integrating Lutetium-177 (177Lu-PSMA-617) into clinical practices and the challenges that we're facing with availability issues. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, New Orleans, Louisiana Alici...

A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore

Details
Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. Biographies: Neal Shore, MD...

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Details
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...

Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans

Details
Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, The VISION Trial Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine VISION trial publication entitled, "Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." In the VISION trial, radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive me...

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...

Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi

Details
Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...

The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris

Details
Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...
email news signup